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despite nasal oxygen, 9 (24%) underwent non-invasive ventilation. Thirty-
three (25%) of 133 patients with systolic arterial pressure >110mmHg were
treated with nitroglycerine. One patient was treated with morphine. Sixteen
patients (10%) underwent echocardiography in the ED. By September 2015,
phase 1 data from 1000 patients will be collected from the 16 hospitals, anal-
ysed and will be presented at the meeting.
Conclusion These initial data show that nitroglycerine, morphine, non-
invasive ventilation, and echocardiography seem not commonly used at the
first point of medical care for patients presenting with ACF. 
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Background Intensive exercise is associated with an increase in left ventric-
ular wall thickness (LVWT) and cavity size. In some cases, a doubt may occur
between an athlete’s heart and hypertrophic cardiomyopathy (HCM), and genetic
testing has been suggested in the diagnostic work-up. The aim of the study was to
assess the accuracy and role of genetic testing to distinguish athlete’s heart from
borderline HCM and make a decision regarding sport/professional activity.
Methods We studied consecutive athletes (intensive sport >10 hours/
weeks; LVWT 12 to 16mm) with a suspicion of borderline HCM according to
the clinical status and cardiac examinations. We studied the accuracy of local
cardiac assessment versus expert referral center (blinded assessment) versus
results of genetic testing (analysis of the 5 main sarcomeric genes). All cardiac
assessments were performed according to ECG, echo, exercise test andcmR
(when available) and were blinded to genetic results.
Results 37 athletes (35 men) were enrolled, mean age: 28±12 years, mean
LVWT was 13.6±1.2mm. A causative mutation was identified in 27% (10/37, in
MYBPC3 / MYH7 / TNNI3 / MYL2 genes) of athletes: among these 10 subjects,
8 had a cardiac diagnosis od suspected HCM and 2 had a suspected diagnosis of
athlete’s heart. Genetic testing rectified cardiac assessment in 5.4% of our popula-
tion. Local cardiac evaluation suspected HCM in 70% (n=26, only 31% with a
mutation) versus 46% (n=17, 47% with a mutation) in expert center (p=0.03). In
subjects without identified genetic mutation, HCM was suspected in 67% of cases
in local center versus 33% in expert center (p=0.01).
Conclusions We report the first systematic evaluation of genetic testing in
athletes with a suspicion of HCM. Genetic testing was able to confirm the
diagnosis of HCM in 27%, including the rectification of cardiac assessment in
5.4%. Our results suggest that genetic testing may have a role in athletes with
a suspicion of borderline HCM.
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Introduction and aim Hypertrophic cardiomyopathy (HCM) represents a
generalized myopathic process affecting both ventricular and atrial myocar-
dium. We aimed to assess LA function by two-dimensional speckle tracking
echocardiography (2DSTE) and its relation with the occurrence of supra-ven-
tricular arrhythmia during the follow-up.
Methods and results We enrolled 105 consecutive patients with HCM on
sinus rhythm and 65 normal subjects matched for age and gender: LV global
longitudinal strain (GLS) was assessed as well as the LA strain: s-wave (LASs).
Patients were followed up for 38 months (20 to 45) to relieve cardiovascular
events, defined as supra-ventricular arrhythmia (Atrial fibrillation and/or atrial
flutter). GLS was significantly lower in patients with HCM compared with con-
trols (–13.81±6.19% vs –21.85±1.46% P<0.001). Patients with HCM had also a
significantly lower LASs compared with controls (24.46±10.75% vs
32.37±3.33%, P<0.01). 14 patients (13.4%) present a cardiovascular event after
a median time of 22 months. LASs was significantly lower in the group of
patients with supra-ventricular arrhythmia compared to the group without supra-
ventricular arrhythmia (19.9±10.40% Vs 26.76±10.25%; p<0.001). In multivar-
iate analysis, interventricular septum>30mm and LV outflow tract gra-
dient>30mmHg were predictors of supra-ventricular arrhythmia (OR=17.38,
95% CI 1.92-157.05,p=0.004; OR=8.6, 95% CI 0.54-6.23, p=0.002; respec-
tively).LA strain was an independant predictor of supra-ventricular arrhythmia:a
cutoff of –20% predicted supra-ventricular events at 22 months with a sensi-
tivity of 80% and a specificity of 86% (OR=4.11, 95% CI 0.021-5.59, P=0.006.
LA myocardial deformation is significantly impaired in patients with HCM
compared to healthy controls, a cutoff value of the LA strain at –20% is associ-
ated with supra-ventricular arythmia on the follow up.
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Background Rest echocardiography plays a role in the diagnosis and risk
stratification of hypertrophic cardiomyopathy (HCM). Indeed, left atrial
enlargement, severe left ventricle (LV) hypertrophy and rest LV outflow tract
(LVOT) gradients ≥50mmHg are sudden cardiac death risk factors as high-
lighted in recent guidelines. Conversely, exercise echocardiography findings
play only a limited role in prognosis evaluations. Therefore, we sought to
determine whether exercise induced changes in myocardial and valvular func-
tions could improve HCM risk stratification.
Methods and results Consecutive HCM patients with a preserved LV ejec-
tion fraction underwent standardized exercise echocardiography (including the
assessment of myocardial function, dynamic left intra-ventricular gradient and
valvular regurgitations) at baseline and were clinically followed for a median of
29.3 months. The primary endpoint was a composite criterion that included
death from any cause, cardiorespiratory arrest, and hospitalization for a cardio-
vascular event. A total of 126 patients were included. Eighteen patients reached
the primary endpoint. According to univariate Cox regression analysis, exercise
LVOT gradient ≥50mmHg (HR=3.31, p=0.01) and significant (≥2/4) exercise
mitral regurgitation (HR=3.64, p<0.01) were associated with the primary end-
point. Patients with significant MR had significantly higher rest and exercise
LVOT gradients (p=0.001 and p=0.001) and larger left atria (p<0.001).
Conclusion Significant exercise mitral regurgitation appears to signifi-
cantly impact the prognoses of HCM patients, and it is also associated with
higher LVOT rest and exercise gradients.
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Background Heart failure (HF) symptoms, related to pulmonary capillary
hypertension, are frequent in hypertrophic cardiomyopathy (HCM). Pulmo-
